Curium Completes Acquisition Of Monrol To Expand Nuclear Medicine Capabilities

KUALA LUMPUR, April 2 (Bernama) -- Curium Pharma (Curium), a global leader in nuclear medicine, has completed its acquisition of Istanbul-based Eczacıbaşı-Monrol Nuclear Products Co (Monrol), further strengthening its Lutetium-177 (Lu-177) production capacity.

In a statement, Curium said the acquisition would support growing global demand for isotopes and ensure supply for its upcoming Lu-177 drug candidates targeting prostate cancer (currently in development) and neuroendocrine tumours (pending approval).

The integration of Monrol enhances Curium’s research and development capabilities while expanding its pipeline of theranostic products. Subject to regulatory approvals, the company also plans to introduce Monrol’s Ga-68 generator globally.

Curium Chief Executive Officer (CEO) for International Markets, Chaitanya Tatineni said the acquisition brings nearly 400 skilled professionals into the company and enhances its capabilities in Lu-177 production and distribution.

Meanwhile, Monrol General Manager, Aydin Kucuk expressed confidence in leveraging Curium’s global reach and expertise to advance nuclear diagnostic solutions and therapies.

In addition, Eczacıbaşı Pharmaceutical and Industrial Investment CEO, Emin Fadıllıoğlu stated that Monrol’s transformation under its leadership had positioned it for further growth within Curium’s global network.

The deal extends Curium’s footprint in the positron emission tomography (PET) and single photon emission computed tomography (SPECT) sectors, increasing from 34 sites across Western Europe and Asia to 46, with the addition of 12 Monrol-owned and partner sites in Eastern Europe and the Middle East and North Africa (MENA) regions.

-- BERNAMA